Median progression-free survival (PFS) improved nonsignificantly from 2.3 to 2.6 months with the addition of nanoliposomal irinotecan to fluorouracil and leucovorin. Overall survival (OS) declined ...
Epidermal Growth Factor Receptor (EGFR) Status in Primary Colorectal Tumors Does Not Correlate With EGFR Expression in Related Metastatic Sites: Implications for Treatment With EGFR-Targeted ...
The US Food and Drug Administration (FDA) has approved irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) in combination with oxaliplatin, fluorouracil, and leucovorin for the first-line ...
Onivyde (irinotecan liposome injection) is a prescription drug used to treat certain types of pancreatic cancer. Onivyde comes as a liquid solution for IV infusion in a healthcare facility, usually ...
A new study published in JCO Precision Oncology has identified a relatively simple method to predict the cancer patients most likely to develop severe toxicities from chemotherapy. If doctors can ...
Tevimbra plus POFI demonstrated high efficacy with a 93.5% objective response rate and 100% disease control rate in advanced gastric cancer. Median progression-free survival was 10.51 months, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback